Early ARA 290 treatment decelerates Alzheimer's-like pathology by boosting Aβ-clearing patrolling monocytes in mice.

Alzheimer's disease (AD) pathology involves amyloid-β (Aβ) deposition and tau hyper-phosphorylation, leading to cognitive decline. Monocytes, particularly the Ly6CLow patrolling subset, are known to modulate Aβ pathology by clearing it from cerebral vasculature, making them a key therapeutic target. Erythropoietin (EPO) shows immunomodulatory and neuroprotective potential in preclinical AD models, but its clinical use is limited by thrombotic risks from its erythropoietic effects. To overcome this, researchers are investigating non-erythropoietic EPO analogues like ARA 290, which may offer the immunomodulatory benefits without the dangerous off-target effects on red blood cell production.

Researchers evaluated the therapeutic potential of ARA 290 using two mouse models of AD: an early-onset model (young APP/PS1 mice) and a late-onset model (aged APP/PS1 mice). They administered ARA 290 systemically in the early-onset model to assess its impact on pathology progression and cognitive function. To confirm the mechanism, they also used chimeric APP/PS1 mice where the Ly6CLow patrolling monocyte subset was selectively depleted. The study measured Aβ burden, cognitive performance, and levels of circulating monocytes and their progenitors in the bone marrow.

In young APP/PS1 mice, early systemic treatment with ARA 290 decelerated the progression of Aβ pathology and improved cognitive functions. The treatment potently increased total monocyte levels by specifically stimulating the generation of the Ly6CLow patrolling subset, which subsequently reduced the overall Aβ burden in the brain. ARA 290 also increased the levels of monocyte progenitors in the bone marrow. However, the therapeutic effects were lost in chimeric mice lacking the Ly6CLow subset, confirming this cell type is essential for the peptide's mechanism of action.

In a late-onset model using aged APP/PS1 mice with advanced pathology, ARA 290 failed to reverse Aβ pathology or increase circulating monocyte levels. This indicates a critical therapeutic window for intervention, where ARA 290 is effective at preventing disease progression but not at reversing established, advanced pathology.